1228 Phase I study of NGR-hTNF, a vascular targeting agent (VTA), in combination withcisplatin in refractory patients (pts) with solid tumoursG. Citterio,F. G. De Braud,V. Gregorc,T. M. De Pas,C. Noberasco,S. Boselli,M. Giovannini,F. Caligaris Cappio,A. Lambiase,C. BordignonEJC SUPPLEMENTS(2009)引用 0|浏览26暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要